TB-500 certificate of analysis explained: what it proves

Last updated 2026-07-25

What is a TB-500 certificate of analysis, exactly?

A certificate of analysis is a lab document tied to one specific batch of material. It typically reports the peptide's identity (confirmed by mass spectrometry), its purity by HPLC (usually expressed as a percentage), and sometimes extra data like endotoxin levels, residual solvents, or moisture content. That's it. A COA is a snapshot of what a lab found in a sample from that batch, at the time it was tested. It is not a safety clearance, not a regulatory approval, and not a guarantee about what's actually in the vial you're holding. The peptide research literature calls TB-500 a synthetic version of an active region of thymosin beta-4, and the analytical chemistry papers written about it are almost entirely about detecting it in doping control, not about certifying commercial products for sale ^{[1] [2]}. That distinction matters a lot when you're reading a COA that a seller hands you.

Is TB-500 the same thing as thymosin beta-4?

No, and this is where a lot of sloppy marketing falls apart. Thymosin beta-4 (Tβ4) is the full-length, naturally occurring protein in the body, involved in cell migration and tissue repair signaling. TB-500 is a shorthand name used in the research and gray-market supply chain for a synthetic peptide built around the active region of that protein, not the whole molecule. Analytical work has specifically characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 that shows up in material sold as TB-500, precisely because regulators and doping labs needed a way to identify it apart from the native protein ^[3]. If a COA just says "thymosin beta-4" without specifying the fragment or sequence tested, that's a red flag, not a reassurance. See our TB-500 vs TB4 peptide comparison for the sequence-level differences that actually matter when you're evaluating a product.

What does a purity percentage on a COA actually tell you?

Purity, usually reported by HPLC as something like "98%" or "99.2%," tells you what fraction of the material in that specific test sample matched the expected peptide, versus other peptide fragments, degradation products, or synthesis byproducts. It says nothing about sterility, endotoxin load, or whether the vial you're holding came from the same batch as the one tested. Recent orthopaedic and sports medicine literature has started cataloging the practical problems with unapproved peptide products directly. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers the application challenges facing therapeutic peptides in orthopaedic practice, including product quality concerns ^[1]. A companion primer in The American Journal of Sports Medicine walks physicians through injectable peptide therapy considerations for sports medicine settings ^[4]. Neither treats a purity percentage alone as sufficient evidence of product safety. A separate 2026 Sports Medicine (Auckland) paper looking at approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance frames the safety and efficacy question directly, and unapproved peptide products like TB-500 fall on the wrong side of that line by definition ^[5].

Does a COA mean TB-500 is FDA-approved or legal to sell?

No. A COA is a private lab test result. It has nothing to do with FDA approval status. TB-500 does not appear in the FDA's Drugs@FDA database of approved drug products, because it isn't one ^[6]. Separately, FDA's compounding framework under 21 U.S.C. 353a lets state-licensed pharmacies compound certain drugs from bulk substances, but only for substances that appear on FDA's 503A or 503B bulk drug substance lists, or that meet other specific criteria ^{[7] [8]}. FDA's own compounding page for bulk substances lays out how that list works and what qualifies ^[9]. A peptide having a COA changes nothing about whether it's on that list or how it can legally be marketed. Under 21 CFR 201.128, a product's "intended use" for regulatory purposes is determined by labeling, advertising, and how it's marketed, not by what a lab report says about purity ^[10]. Selling a peptide "for research use only" while implying it's meant for injection into a person is exactly the kind of intended-use mismatch that gets products flagged.

Can a COA be faked, or does it come from an independent lab?

Both things happen in this market, and you often can't tell from the PDF alone. Some COAs come from independent third-party labs with no financial stake in the seller. Others come from labs the seller owns, or from labs willing to sign off on whatever numbers they're handed. Things to actually check: does the COA name a specific accredited lab you can look up? Does it include a batch or lot number that matches what's printed on the vial? Does it list the test method (HPLC, mass spec) and raw data, more than a headline percentage? Does the date make sense relative to when you're buying? None of this is peptide-specific paranoia. It's the same due diligence you'd want on any unregulated injectable product, and it's why the responsible path is going through a provider-reviewed source with pharmacy-level oversight rather than a loose-panel vendor site, which we cover more in TB-500 for sale.

How is TB-500 actually detected and measured in lab testing?

The most detailed public data on measuring TB-500 doesn't come from supplement industry COAs. It comes from anti-doping and forensic chemistry labs trying to catch it in athletes and racehorses. A 2024 study in the Journal of Chromatography B developed a method to simultaneously quantify TB-500 and its metabolites in vitro and in rats, using UHPLC coupled to Q-Exactive Orbitrap MS/MS, and screened the resulting fragments for wound healing activity ^[11]. That's a genuinely rigorous quantification method, but it was built for research and doping detection, not for routine commercial batch testing. Older doping-control papers describe LC-MS methods for detecting TB-500 in equine urine and plasma ^[12], in human doping samples more broadly ^{[2] [13]}, and in horse plasma alongside six other bioactive peptides ^[14]. There's also work on how TB-500 behaves during sample prep, including a 2017 study on adsorption effects that showed TB-500, along with insulin lispro, Synacthen, and GHRP-5, can stick to labware and equipment in ways that mess with recovery and quantification if a lab isn't careful ^[15]. If professional anti-doping labs have to account for adsorption losses to get accurate numbers, a basic commercial COA using simpler methods deserves some skepticism about precision.

Why does WADA care about TB-500 detection at all?

Because thymosin beta-4 and TB-500 are prohibited in sport, and the analytical chemistry community has spent over a decade building methods specifically to catch it. This isn't a hypothetical compliance issue for competitive athletes. A 2012 study in Drug Testing and Analysis synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 specifically because it was "suspected to possess doping potential" ^[3]. Review articles in Expert Review of Proteomics ^[13] and the Journal of Pharmaceutical and Biomedical Analysis ^[2] cover the broader challenge of detecting peptidic drugs and drug candidates in sports doping, with TB-500 as a named example. More technical papers cover in vitro metabolism models for small peptide hormones in drug testing ^[16], comparisons of enzyme, serum, liver, and kidney microsome models for metabolizing synthetic doping peptides ^[17], solid-phase extraction methods for isolating small bioactive peptides from urine ^[18], and screening methods for peptides under 2 kDa using direct urine injection with ion mobility mass spectrometry ^[19]. If you compete under WADA rules or any testing body that follows the WADA Prohibited List, a COA showing "98% pure" does nothing to make TB-500 use compliant.

Does a high purity score mean TB-500 works or is safe?

No, and this is the gap most sellers hope you won't notice. Purity tells you what's in the vial. It says nothing about whether the human evidence supports the effect being sold to you. The honest state of the evidence: TB-500 research is overwhelmingly preclinical, meaning cell culture and animal studies, not controlled human trials. The 2024 Journal of Chromatography B paper that quantified TB-500 metabolites also screened them for wound healing activity, but that screening was in vitro, in lab dishes, not in people ^[11]. A 2026 Frontiers in Aging review on therapeutic peptides in gerontology covers mechanisms and applications relevant to healthy aging broadly, again at the mechanism and preclinical level ^[20]. The practical translation: even a COA with a perfect purity number, from a legitimate independent lab, testing an accurately labeled batch, still tells you nothing about dosing that works in humans or long-term safety in humans. For that side of the question, our TB-500 evidence page and TB-500 cycle length guide cover what the preclinical data can and can't support.

What should a trustworthy TB-500 COA actually include?

Here's the realistic checklist, based on what analytical chemists actually test for in rigorous peptide characterization work, not marketing copy.

Even a COA hitting every box on this table is still describing one tested batch. It's not a blanket guarantee about every vial with that lot number, and it's definitely not a substitute for sourcing through a channel with actual pharmacy accountability behind it.

Is there a standalone TB-500 product, or is it always blended?

There is no standalone TB-500 product available through legitimate, provider-reviewed channels. In practice, TB-500 research material is dispensed as a BPC-157/TB-500 blend, not sold on its own. This matters directly for reading a COA. If you're evaluating a blend, the certificate needs to show purity and identity data for both peptides separately, not one combined number. A COA that only tests total peptide content without breaking out BPC-157 and TB-500 individually tells you much less than it looks like it does. TB-500 Co works with a provider-reviewed pharmacy partner for exactly this reason: batch documentation and pharmacy-level accountability matter more here than a vendor's marketing claims about purity. If you're weighing the BPC-157 pairing specifically, that's covered in more depth on our main TB-500 evidence page.

What should I actually do before trusting a TB-500 COA?

Treat the COA as one data point, not proof of anything beyond what it literally states. Verify the lab is real and independent. Check that the lot number on the certificate matches your vial. Confirm the test method and look for a sequence or fragment identity, more than a vague peptide name. Don't let a 99% purity number distract you from the fact that TB-500 remains an unapproved substance with a preclinical evidence base ^{[5] [1]}. If you're weighing where to source from at all, understand there's no standalone TB-500 SKU, it comes as a BPC-157/TB-500 blend, and the provider-reviewed route with pharmacy oversight is the more defensible option compared to anonymous vendor sites. See TB-500 for sale for how that sourcing decision actually breaks down, and TB-500 how to inject plus TB-500 injection sites if you're past the sourcing question and into the practical handling of it.

Frequently asked questions

What is a certificate of analysis for a peptide like TB-500?

It's a lab report for one specific batch, showing test results like purity by HPLC, identity confirmation by mass spectrometry, and sometimes endotoxin or heavy metal levels. It documents what a lab found in that sample. It is not an approval, safety certification, or legal clearance for the product.

Does a TB-500 COA mean the product is FDA-approved?

No. TB-500 doesn't appear in FDA's Drugs@FDA database of approved products ^[7]. A COA is a private lab document unrelated to FDA approval status, and unapproved peptides don't become approved because a lab tested a batch for purity.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the full native protein. TB-500 is shorthand for a synthetic peptide built around an active fragment of it, specifically characterized in the literature as an N-terminal acetylated 17-23 fragment ^[3]. Sources that use the names interchangeably are being imprecise.

Can a COA be faked or come from a non-independent lab?

Yes, and there's no way to tell from the document alone. Check for a named, verifiable accredited lab, a lot number matching your vial, and raw test data with the method used, rather than trusting a headline purity percentage on its own.

Does high purity on a COA mean TB-500 is safe or effective?

No. Purity describes what's in the vial, not whether the product works or is safe in humans. TB-500 evidence remains overwhelmingly preclinical, from cell and animal studies ^[12][21], and a purity number says nothing about human dosing or long-term safety.

Is TB-500 banned for athletes?

Yes, TB-500 and thymosin beta-4 are prohibited under WADA rules, and analytical chemistry labs have built extensive detection methods specifically to catch it in doping samples, in both human and equine testing ^[2][13][14]. A COA has no bearing on this prohibition.

How do labs actually detect TB-500 in a sample?

Anti-doping and forensic labs use liquid chromatography paired with mass spectrometry, including advanced Orbitrap MS/MS methods, to identify TB-500 and its metabolites in urine, plasma, or tissue ^[12][13][15]. These are far more rigorous than most commercial COA testing.

Can TB-500 stick to lab equipment and affect test results?

Yes. A 2017 study found TB-500, along with insulin lispro, Synacthen, and GHRP-5, shows adsorption effects that can reduce recovery during sample prep if labs don't account for it ^[16]. This is a reason to be cautious about precision claims on basic commercial COAs.

Is there a standalone TB-500 product I can buy?

No. TB-500 research material is dispensed as a BPC-157/TB-500 blend, not sold as a standalone SKU through legitimate, provider-reviewed channels. A COA for a blend should show separate purity and identity data for each peptide, not one combined figure.

What should a COA include to be trustworthy?

A named accredited lab, a batch/lot number matching your vial, the test method used (HPLC or LC-MS), specific sequence or fragment identity, a recent test date, and ideally endotoxin or sterility data if the material is meant for injection.

Does a COA prove the vial I received matches the batch tested?

No. A COA documents results for a sample from a specific batch at the time of testing. It doesn't guarantee every vial labeled with that lot number is identical, especially from sellers without pharmacy-level chain-of-custody controls.

Why do TB-500 COAs from research chemical sellers vary so much in quality?

Because there's no regulatory requirement forcing a standard format or independent verification for unapproved research peptides. Quality depends entirely on whether the seller uses an accredited, independent lab and discloses full method and batch data, which many gray-market vendors don't.

Sources

1. PubMed, Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews (2026): Reviews therapeutic peptides in orthopaedics, including application challenges for products like TB-500.
2. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Covers analytical approaches for detecting emerging therapeutics and non-approved drugs, including TB-500, in doping controls.
3. PubMed, Drug Testing and Analysis (2012): Synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500, flagged for doping potential.
4. PubMed, The American Journal of Sports Medicine (2026): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy considerations.
5. PubMed, Sports Medicine (Auckland, N.Z.) (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
6. FDA, Drugs@FDA database: TB-500 does not appear as an FDA-approved drug product in the Drugs@FDA database.
7. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Governs pharmacy compounding conditions under federal law, including bulk substance requirements.
8. eCFR, 21 CFR 216.23 (final 503A Bulks List): Lists bulk drug substances that may be used in 503A compounding, relevant to what compliant compounding pharmacies can legally use.
9. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains FDA's process and criteria for bulk drug substances used in compounding.
10. eCFR, 21 CFR 201.128: Defines how a product's intended use is determined by labeling and marketing, not by lab test documentation.
11. PubMed, Journal of Chromatography B (2024): Developed UHPLC-Q-Exactive Orbitrap MS/MS method to quantify TB-500 and metabolites in vitro and in rats, with in vitro wound healing screening.
12. PubMed, Journal of Chromatography A (2012): Developed LC-MS doping control method for detecting TB-500 in equine urine and plasma.
13. PubMed, Expert Review of Proteomics (2014): Reviews methods and challenges for detecting peptidic drugs and analogs like TB-500 in sports doping.
14. PubMed, Analytical and Bioanalytical Chemistry (2013): Describes doping control LC-MS analysis of seven bioactive peptides, including TB-500, in horse plasma.
15. PubMed, Analytical Biochemistry (2017): Found TB-500, along with insulin lispro, Synacthen, and GHRP-5, shows adsorption effects affecting recovery during sample preparation.
16. PubMed, Journal of Peptide Science (2015): Covers in vitro models used for metabolic studies of small peptide hormones in sport drug testing.
17. PubMed, Journal of Proteomics (2016): Compares in vitro model systems (enzymes, serum, liver/kidney microsomes) for metabolizing synthetic doping peptides.
18. PubMed, Drug Testing and Analysis (2016): Describes solid-phase extraction methods for isolating small bioactive peptides from human urine for testing.
19. PubMed, Journal of Separation Science (2016): Describes a screening method for peptides under 2 kDa using direct urine injection and ion mobility mass spectrometry.
20. PubMed, Frontiers in Aging (2026): Reviews mechanisms and applications of therapeutic peptides in gerontology, at the mechanistic/preclinical level.